David A. Siegel Bio Atla, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 153,300 shares of BCAB stock, worth $249,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153,300

Previous 299,700 48.85%

Holding current value

$249,878

Previous $1.03 Million 79.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $200,568 - $573,888	-146,400 Reduced 48.85%	153,300 $210,000
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $72,944 - $134,248	38,800 Added 14.87%	299,700 $1.03 Million
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $5,334 - $13,356	4,200 Added 1.64%	260,900 $641,000
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $77,690 - $140,299	-45,700 Reduced 15.11%	256,700 $436,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $140,934 - $192,726	-49,800 Reduced 14.14%	302,400 $907,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $6,899 - $24,750	3,000 Added 0.86%	352,200 $943,000
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $55,352 - $96,888	-8,800 Reduced 2.46%	349,200 $2.88 Million
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $178,752 - $721,696	-60,800 Reduced 14.52%	358,000 $2.76 Million
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $251,340 - $634,840	118,000 Added 39.23%	418,800 $1.19 Million
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $655,686 - $2.81 Million	149,700 Added 99.07%	300,800 $1.5 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $2.87 Million - $4.68 Million	151,100 New	151,100 $2.97 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

22.1M

Call Options Held

10.7K

Put Options Held

7.4K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account